RecruitingPhase 1NCT06732180

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GT-02287 in Parkinson's Disease

An Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GT-02287 in Participants With Parkinson's Disease With or Without a Pathogenic GBA1 Mutation

Sponsor

Gain Therapeutics, Inc.

Enrollment

20 participants

Start Date

Feb 21, 2025

Study Type

INTERVENTIONAL

Conditions

Parkinson Disease

Summary

The main goal of this clinical trial is to learn about the safety and tolerability of GT-02287. The questions it aims to answer are: * What medical problems do participants have when taking GT-02287? * How is GT-02287 absorbed, distributed, and removed from the body of participants over time (pharmacokinetics)? * Are there any biological effects of GT-02287 in blood and in cerebrospinal fluid that could be beneficial for people with Parkinson's disease? Participants will: * visit the clinic to assess if they qualify for the study (30-day Screening Period) * if eligible, receive GT-02287 once a day every day for 90 days (90-day Open Label Treatment period) * visit the clinic the first day of treatment, after the first 2 weeks of treatment, and every month during the 90-day Treatment Period. * visit the clinic to assess how they are doing 14 days after the end of GT-02287 treatment (14-day Follow-Up Period).

Eligibility

Min Age: 30 YearsMax Age: 85 Years

Inclusion Criteria13

Able and willing to provide written informed consent and be willing to comply with the requirements and restrictions of the study
Any sex, ≥30 and ≤85 years of age
Diagnosis of PD based on MDS criteria
Within 7 years of PD diagnosis
Body mass index of ≥18 and ≤40 kg/m2, and a body weight ≥45 kg and ≤120 kg
Willing to provide a blood sample for PD-related genetic testing
Hoehn \& Yahr 1-3, inclusive
No severe motor fluctuations or disabling dyskinesias based on the investigator's clinical assessment
Naïve to pharmacological treatment for PD or on stable PD medication for ≥3 months prior to Screening, including ≥4 weeks at the same dose(s) immediately before Screening
Not pregnant or breastfeeding
If participant is either of childbearing potential or produces potentially viable sperm, participant must agree to use 2 forms of contraception (barrier method and a second highly effective form of birth control/contraception, as defined in the protocol) if engaging in potentially reproductive intercourse (with a partner who produces potentially viable sperm or is of childbearing potential, respectively)
Agreeing to not participate in another investigational study while taking part in this study
For participants with known GBA1 mutations, presence of a GBA1 mutation that has been associated with an increased risk of PD

Exclusion Criteria14

Other neurological disorders, including but not limited to Alzheimer's disease, amyotrophic lateral sclerosis, frontotemporal dementia, progressive supranuclear palsy, corticobasal syndrome, Huntington's disease, multiple system atrophy, dementia with Lewy bodies, secondary (e.g. drug-induced) parkinsonism, multiple sclerosis, or epilepsy
A history of Gaucher disease or homozygous for a GBA1 pathogenic variant known to be associated with GD or compound heterozygous for 2 alleles that are known to be associated with GD.
Known PD-associated LRRK2 pathogenic variant or other PD-associated genetic mutations other than GBA1
Dementia or a moderate cognitive impairment (score ≥17 on the Montreal Cognitive Assessment)
Hypersensitivity to GT-02287 or any of its excipients
Concomitant medications metabolized primarily by cytochrome P450 3A4 (CYP3A4) that have a narrow therapeutic window, concomitant medications that are substrates of breast cancer resistance protein and/or P-glycoprotein and that have a narrow therapeutic window, concomitant medications that are potent inhibitors or inducers of CYP3A4
Use of dopamine antagonists (antipsychotics) or anticholinergic medications
Concomitant disease including, but not limited to cardiovascular conditions, diabetes, autoimmune disease, cancer, active infectious disease, psychotic disorders and symptoms, depressive symptoms, drug and/or alcohol misuse as defined in the protocol
Malabsorption or relevant disorder which may impact the absorption of GT-02287
Clinically significant abnormalities in laboratory test
Contraindications to lumbar puncture (LP)
Blood donation \>500 mL within 3 months
Unable to comply with restrictions on food products, smoking, and /or alcohol use as defined in protocol
participation in any interventional clinical study within 3 months or 5 half-lives, whichever is longer, prior to Screening

Interventions

DRUGGT-02287

Dose of 13.5 mg/kg/day (plus/minus 2 mg/kg/day based on body weight) to be administered orally once a day for 90 days. Dosage form: powder in sachet (200 mg of GT-02287 per sachet) for reconstitution with a suspending agent